A Research Study to See How Insulin Icodec Helps People With Type 1 Diabetes Control Their Blood Sugar
NCT ID: NCT07160816
Last Updated: 2026-01-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
245 participants
OBSERVATIONAL
2025-08-28
2027-01-20
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of LY900027 Given by Insulin Pump to Participants With Type 1 Diabetes Mellitus
NCT04161976
A Research Study to Compare a New Weekly Insulin, Insulin Icodec, and an Available Daily Insulin, Insulin Degludec, Both in Combination With Mealtime Insulin in People With Type 1 Diabetes (ONWARDS 6)
NCT04848480
General Use-results Surveillance With Awiqli in Patients With Diabetes Mellitus
NCT06807190
A Study of LY900014 Formulation in Participants With Type 1 Diabetes Mellitus Using Insulin Pumps
NCT02703324
A Study of LY900014 Administered in Participants With Type 1 Diabetes Using an Insulin Pump
NCT03056456
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Insulin icodec
Participants with T1D will be treated with commercially available insulin icodec according to routine clinical practice at the discretion of the treating physician.
Insulin icodec
Participants with T1D will be treated with commercially available insulin icodec.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Insulin icodec
Participants with T1D will be treated with commercially available insulin icodec.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* The decision to initiate treatment with commercially available insulin icodec has been made by the participant/legally acceptable representative (LAR) and the treating physician before and independently from the decision to include the participant in this study.
* Male or female, age greater than or equal to (≥) 18 years at the time of signing informed consent.
* Diagnosed with T1D ≥ 1 year before signing informed consent.
* Treated with multiple daily insulin injections (daily basal insulin analogue and bolus insulin analogue regimen) ≥ 6 months before signing informed consent.
* Available HbA1c value less than or equal to (≤) 90 days prior to the 'Initiation visit' (V1) or HbA1c measurement taken in relation with the 'Initiation visit' (V1) if in line with local clinical practice.
* Treatment naïve to once-weekly insulin prior to the 'Initiation Visit' (V1).
Exclusion Criteria
* Treatment with any investigational drug within 30 days prior to enrolment into the study.
* Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Novo Nordisk A/S
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Clinical Transparency (dept. 2834)
Role: STUDY_DIRECTOR
Novo Nordisk A/S
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hausärztliche und Diabetologische Praxis Pirna
Pirna, LÄK Sachsen, Germany
Zuckerpraxis Dr. Ewald Jammers
Bramsche, , Germany
Studiengesellschaft Dres. Könemann/Steinmann GbR
Bünde, , Germany
Diabeteszentrum-Do Dres. K U. Ch. Busch GbR
Dortmund, , Germany
Diabeteszentrum Duisburg-Mitte
Duisburg, , Germany
MVZ im Altstadt-Carree Fulda GmbH - Zentrum für klinische Studien
Fulda, , Germany
Gemeinschaftspraxis Dr. Martin Grüneberg
Herne, , Germany
Mesut Durmaz, Hof
Hof, , Germany
Dr. Carola Lüke
Jerichow, , Germany
Diabetespraxis Kiel
Kiel, , Germany
Praxis Am Oberen Tor - Dr. Simon-Wagner
Lichtenfels, , Germany
Diabetologie Dr. Eidenmüller
Marburg, , Germany
Dr. Bernhard Landers
Mayen, , Germany
Diabeteszentrum Bogenhausen
München, , Germany
Medicover Neu-Ulm MVZ
Neu-Ulm, , Germany
Diabetespraxis Oranienburg
Oranienburg, , Germany
Diabetesschwerpunktpraxis Dr. Martina Lange
Rheinbach, , Germany
Med.Versorgungszentrum Riesa-Dr. Bieler
Riesa, , Germany
Dr. med. Carsten Schürfeld, GZ-Vauban
Saarlouis, , Germany
Diabetespraxis Schorndorf Dr. Hensel
Schorndorf, , Germany
Praxis Dr. Zimmermann
Sonsbeck, , Germany
Endokrinologikum Ulm
Ulm, , Germany
Diabetespraxis Viersen
Viersen, , Germany
Ospedale San Raffaele S.r.l. - Unità Clinica Endocrinologia
Milan, Lombardy, Italy
Azienda Sanitaria Locale Città di Torino - Ambulatorio Endocrinologia e Malattie Metaboliche
Turin, Piedmont, Italy
AUSL Toscana Nord Ovest - Ospedali Riuniti di Livorno - Diabetologia e Malattie del Metabolismo
Livorno, Tuscany, Italy
AUSL Toscana Nord Ovest - Cittadella della Salute Campo di Marte - Diabetologia Lucca e Valle del Serchio
Lucca, Tuscany, Italy
Azienda Ospedaliera Papa Giovanni XXIII
Bergamo, , Italy
Azienda Ospedaliero-Universitaria Renato Dulbecco
Catanzaro, , Italy
Azienda Ospedaliera Luigi Sacco
Milan, , Italy
A.O.U. Università Studi della Campania "Luigi Vanvitelli"
Naples, , Italy
Azienda Ospedaliera di Perugia;Ospedale S. Maria della Misericordia
Perugia, , Italy
DIABETOLOGIA Ravenna AUSL della Romagna
Ravenna, , Italy
Universita Degli Studi Di Roma La Sapienza - Policlinico Umberto I Medicina Sperimentale
Roma, , Italy
Fondazione Policlinico Universitario Agostino Gemelli IRCCS - Dipartimento di scienze Mediche e Chirurgiche
Rome, , Italy
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
U1111-1316-7988
Identifier Type: OTHER
Identifier Source: secondary_id
NN1436-8404
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.